Forum Financial Management LP Raises Stock Holdings in AbbVie Inc. $ABBV

Forum Financial Management LP increased its position in AbbVie Inc. (NYSE:ABBV) by 16.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 72,626 shares of the company’s stock after purchasing an additional 10,481 shares during the period. Forum Financial Management LP’s holdings in AbbVie were worth $16,594,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Chelsea Counsel Co. bought a new stake in AbbVie in the third quarter worth $26,000. Westend Capital Management LLC bought a new stake in AbbVie in the fourth quarter worth $29,000. Texas Capital Bancshares Inc TX bought a new stake in AbbVie in the third quarter worth $31,000. Caitlin John LLC bought a new stake in AbbVie in the third quarter worth $33,000. Finally, Legacy Bridge LLC boosted its holdings in AbbVie by 3,800.0% in the fourth quarter. Legacy Bridge LLC now owns 156 shares of the company’s stock worth $36,000 after acquiring an additional 152 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on ABBV. Berenberg Bank set a $275.00 target price on AbbVie in a report on Tuesday, January 20th. Cantor Fitzgerald dropped their target price on AbbVie from $250.00 to $240.00 and set an “overweight” rating on the stock in a report on Wednesday, April 8th. Evercore dropped their target price on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $253.00.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $208.29 on Friday. The company has a market cap of $368.28 billion, a P/E ratio of 88.26, a PEG ratio of 0.74 and a beta of 0.38. AbbVie Inc. has a 1 year low of $168.54 and a 1 year high of $244.81. The stock’s fifty day moving average price is $219.00 and its 200-day moving average price is $223.52.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the company posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is presently 293.22%.

Insiders Place Their Bets

In other news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.06% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New clinical catalysts — AbbVie’s Phase 4 head‑to‑head psoriasis study could create a meaningful commercial catalyst if results favor its therapy, supporting upside expectations for market share and pricing power. AbbVie’s Head-to-Head Psoriasis Study Sets Up New Catalyst for ABBV Investors
• Positive Sentiment: Pipeline expansion into obesity — AbbVie launched a Phase 1 trial for ABBV‑295, signaling R&D diversification beyond immunology and potential long‑term upside if early data show promise. AbbVie Steps Deeper Into Obesity Market With New Phase 1 ABBV-295 Trial
• Positive Sentiment: Real‑world HCV data could shore up legacy franchise value — retrospective safety/efficacy analyses for Glecaprevir/Pibrentasvir may support prescribing and lifecycle value. AbbVie’s Real‑World HCV Study: What G/P Safety Data Could Mean for ABBV Investors
• Positive Sentiment: Value/dividend thesis — bullish retail/analyst pieces argue AbbVie’s strong dividend yield, cash flows, and durable immunology franchises make it attractive to buy on weakness. This supports demand from income-oriented investors. Why AbbVie Is a No-Brainer Stock to Buy on the Dip
• Positive Sentiment: Commercial momentum for Skyrizi and Rinvoq — coverage notes strong sales growth for these franchises, which underpins revenue trajectory and offsets some concerns about valuation and technical weakness. AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock
• Neutral Sentiment: Market opportunity context — reports on the Middle East & Africa biosimilars market list AbbVie among players; this highlights long‑term opportunity and competitive pressures from biosimilars but is not an immediate stock mover. Middle East and Africa Biosimilars Market Trends Report 2026-2035, Profiles of AbbVie, Amgen, …
• Neutral Sentiment: Sector reports (thyroid eye disease) and comparisons to peers — market analyses and a Pfizer vs. AbbVie piece provide framing on relative strengths and risks but add mixed conclusions rather than a clear near-term catalyst. Thyroid Eye Disease Treatment Market Research Report 2026 Featuring Amgen, … AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit
• Negative Sentiment: Technical pressure — multiple outlets highlight ABBV trading below its 50‑ and 200‑day moving averages, a short‑term bearish signal that can trigger further selling by technical traders and funds. That is likely the primary driver of today’s downward price move. AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.